Immunic, Inc. (NASDAQ:IMUX) Receives Consensus Recommendation of “Buy” from Brokerages

Shares of Immunic, Inc. (NASDAQ:IMUX) have earned a consensus recommendation of “Buy” from the eight ratings firms that are presently covering the company, Marketbeat Ratings reports. Six equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating on the company. The average 1-year price objective among brokerages that have covered the stock in the last year is $12.67.

Several research analysts have recently issued reports on the company. StockNews.com cut Immunic from a “hold” rating to a “sell” rating in a research note on Monday, November 11th. D. Boral Capital restated a “buy” rating and set a $17.00 price objective on shares of Immunic in a research note on Tuesday, January 7th. Finally, HC Wainwright assumed coverage on shares of Immunic in a report on Monday, November 25th. They issued a “buy” rating and a $10.00 price objective on the stock.

Immunic Price Performance

Shares of IMUX stock opened at $0.99 on Friday. The business has a fifty day moving average of $1.12 and a 200 day moving average of $1.32. Immunic has a 1 year low of $0.97 and a 1 year high of $2.11. The firm has a market capitalization of $88.85 million, a price-to-earnings ratio of -0.80 and a beta of 1.88.

Insider Activity

In other news, Director Richard Alan Rudick bought 87,300 shares of the stock in a transaction dated Tuesday, November 12th. The shares were acquired at an average cost of $1.15 per share, with a total value of $100,395.00. Following the purchase, the director now directly owns 87,300 shares in the company, valued at $100,395. The trade was a ∞ increase in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Insiders own 3.00% of the company’s stock.

Hedge Funds Weigh In On Immunic

A number of large investors have recently bought and sold shares of IMUX. Virtu Financial LLC acquired a new stake in Immunic in the third quarter valued at approximately $50,000. HB Wealth Management LLC acquired a new stake in Immunic in the 4th quarter valued at $81,000. Jane Street Group LLC grew its stake in Immunic by 121.4% in the 3rd quarter. Jane Street Group LLC now owns 70,299 shares of the company’s stock valued at $116,000 after acquiring an additional 38,553 shares during the period. Connor Clark & Lunn Investment Management Ltd. increased its holdings in Immunic by 70.8% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 102,257 shares of the company’s stock worth $169,000 after acquiring an additional 42,383 shares in the last quarter. Finally, State Street Corp raised its position in Immunic by 7.5% during the third quarter. State Street Corp now owns 167,145 shares of the company’s stock worth $276,000 after acquiring an additional 11,642 shares during the period. Institutional investors and hedge funds own 51.82% of the company’s stock.

About Immunic

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.